Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 34 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR EMA Recommends Extension of Indications for Talazoparib November 27, 2023 Νέος βιοδείκτης για τις γυναίκες πριν την εμμηνόπαυση August 1, 2019 EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria October 2, 2020 President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... February 3, 2022 Load more HOT NEWS Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness... Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... Changes in Metabolism Help Melanomas Spread
